公开(公告)号：US20220395637A1

公开(公告)日：2022-12-15

申请号：US17839645

申请日：2022-06-14

Applicant: INSULET CORPORATION

Inventor： Yibin ZHENG ,  Joon Bok LEE ,  Jason O'CONNOR

IPC: A61M5/172 ,  A61M5/142

Abstract: The disclosed embodiments are directed to methods for determining, based on input from a manual insulin delivery device, for example, an insulin pen, a proper bolus dosing to be delivered by an AID system, to assess the sufficiency of the user-administered basal dose of long-acting insulin and to recommend any changes to the long-acting delivery following a daily analysis of the user's blood glucose readings.

公开(公告)号：US20220168505A1

公开(公告)日：2022-06-02

申请号：US17534129

申请日：2021-11-23

Applicant: Insulet Corporation

Inventor： Mengdi LI ,  Yibin ZHENG ,  Joon Bok LEE ,  Jason O'CONNOR

IPC: A61M5/172

Abstract: Processes and devices are disclosed that are configured to respond to changes in a user's blood glucose caused by ingestion of a meal. Ingestion of the meal may be announced by a user input or by a meal detection algorithm that requires no user input. The responsive device and processes determine a carbohydrate-compensation insulin dosage based on a user's blood glucose history, external data related to the user's meal history, or based on a user's response to previous carbohydrate-compensation insulin dosages. In addition, a correction insulin dosage may be calculated to cover any gap between a starting blood glucose and a target blood glucose. A user's response to a sum of the carbohydrate-compensation insulin dosage and the correction insulin dosage may be delivered. Based on the user's response, the disclosed examples may determine modifications to the carbohydrate-compensation insulin dosage, the correction insulin dosage, or both.

公开(公告)号：US20220088303A1

公开(公告)日：2022-03-24

申请号：US17027191

申请日：2020-09-21

Applicant: Insulet Corporation

Inventor： Joon Bok LEE ,  Yibin ZHENG ,  Steven CARDINALI ,  Jason O'CONNOR

IPC: A61M5/172 ,  A61M5/168

Abstract: Methods and apparatuses for performing an insulin infusion process are described. For example, an apparatus may include at least one memory and logic coupled to the at least one memory. The logic may operate to determine a basal parameter for a patient based on a type 2 diabetes (T2D) multiple daily injection (MDI) information of the patient, the basal parameter indicating a basal infusion rate, determine an additional insulin (Iadd) value based on a mean blood glucose difference (BGdiff) information associated with the patient, determine an insulin volume to infuse into the patient based on the basal parameter and Iadd, and administer the insulin volume to the patient. Other embodiments are described.

公开(公告)号：US20220062550A1

公开(公告)日：2022-03-03

申请号：US17412684

申请日：2021-08-26

Applicant: Insulet Corporation

Inventor： David NAZZARO ,  Jason O'CONNOR ,  Ian MCLAUGHLIN ,  Joon Bok LEE ,  Thomas METZMAKER ,  Bret CHRISTENSEN ,  Philip HILLDALE

IPC: A61M5/172 ,  A61M5/142

Abstract: Embodiments of the present disclosure relate to approaches for transitioning a drug delivery device from a low-energy sleep state to a high-energy active state. In some embodiments, a system may include a drug delivery device, the drug delivery device including a pump mechanism coupled to a reservoir for expelling a liquid drug from the reservoir; and an activation component communicatively coupled to the pump mechanism. The activation component may include at least one of a sensor and a mechanical activation device, and a wake-up circuit operable to receive an input from the sensor or the mechanical activation device, wherein the input indicates a change in a device characteristic. Based on the change in the device characteristic, the wake-up circuit may be further operable to transition the drug delivery device from a low-energy state to an active state.

公开(公告)号：US20220031944A1

公开(公告)日：2022-02-03

申请号：US16945246

申请日：2020-07-31

Applicant: Insulet Corporation

Inventor： Yibin ZHENG ,  Joon Bok LEE ,  Jason O'CONNOR

IPC: A61M5/172 ,  A61M5/142 ,  A61K38/28 ,  G16H20/17 ,  G16H40/67 ,  G05B15/02 ,  G05D7/06

Abstract: Disclosed are techniques to establish a modified pump rate that mitigates the effects of a pump occlusion and enables a recommended dosage of insulin to be output by a pump mechanism over the course of a control cycle. In an example, the pump rate may be reduced by adding a calculated time interval between application of actuation commands to extend the amount of time over which insulin may be output by the pump mechanism.

公开(公告)号：US20210308377A1

公开(公告)日：2021-10-07

申请号：US16840483

申请日：2020-04-06

Applicant: INSULET CORPORATION

Inventor： Mengdi LI ,  Joon Bok LEE ,  Jason O'CONNOR ,  Yibin ZHENG

IPC: A61M5/172 ,  G16H40/67 ,  G16H10/60 ,  G16H20/17 ,  G16H50/20 ,  G16H50/70 ,  G16H10/40 ,  G16H50/30 ,  G16H50/50

Abstract: Disclosed are techniques to establish initial settings for an automatic insulin delivery device. An adjusted total daily insulin (TDI) factor usable to calculate a TDI dosage may be determined. The adjusted TDI factor may be a TDI per unit of a physical characteristic of the user (e.g., weight) times a reduction factor. The adjusted TDI factor may be compared to a maximum algorithm delivery threshold. Based on the comparison result, the application or algorithm may set a TDI dosage and output a control signal. Blood glucose measurement values may be collected from a sensor over a period of time. A level of glycated hemoglobin of the blood may be determined based on the obtained blood glucose measurement values. In response to the level of glycated hemoglobin, the set TDI dosage may be modified. A subsequent control signal including the modified TDI dosage may be output to actuate delivery of insulin.

公开(公告)号：US20210236730A1

公开(公告)日：2021-08-05

申请号：US17166072

申请日：2021-02-03

Applicant: Insulet Corporation

Inventor： Joon Bok LEE ,  Ashutosh ZADE ,  Jason O'CONNOR ,  Yibin ZHENG ,  Steven CARDINALI

IPC: A61M5/172 ,  G16H20/17 ,  G16H10/60 ,  G16H20/30 ,  G16H50/20

Abstract: In an automated insulin delivery device, fuzzy logic may be applied to the responding to the possibility of a user taking additional action that may affect the blood glucose concentration. Fuzzy sets may be defined for empirically derived different likelihoods of the user taking such additional action based on correlated factors. A membership function may be provided for each fuzzy set. The membership function may provide a probability of membership in the set based on a parameter. Each fuzzy set may have a response that is reflective of the likelihood of additional user action associated with the fuzzy set. The responses by the AID device to each of these cases may reflect the probability of each such case occurring as evidenced by empirical data.

公开(公告)号：US20210187197A1

公开(公告)日：2021-06-24

申请号：US17123378

申请日：2020-12-16

Applicant: Insulet Corporation

Inventor： Ashutosh ZADE ,  Joon Bok LEE ,  Yibin ZHENG ,  Jason O'CONNOR

IPC: A61M5/172 ,  A61M5/142 ,  G16H20/17

Abstract: Disclosed are devices, a system, methods and computer-readable medium products that provide techniques to implement functionality to determine when to softened upper bounds of drug delivery and how much to soften the upper bound. Future blood glucose measurement values may be predicted by calculating deviations between predicted blood glucose measurement values and additional blood glucose measurement values. A gain parameter may be determined for use with a model of predicting a user's blood glucose measurement values and determining future drug dosages. Safety constraints may be determined based on an evaluation of missing blood glucose measurement values. In addition, safety constraints may be determined based on an evaluation of a user's increased interaction with an automatic drug delivery device. A bolus uncertainty metric to determine an amount of insulin to be provided in a bolus dosage in response to a bolus request may be calculated.

公开(公告)号：US20210170104A1

公开(公告)日：2021-06-10

申请号：US17112314

申请日：2020-12-04

Applicant: INSULET CORPORATION

Inventor： Yibin ZHENG ,  Joon Bok LEE ,  Steven CARDINALI ,  Jason O'CONNOR ,  Eric BENJAMIN ,  Ian MCLAUGHLIN ,  David NAZZARO ,  Ashutosh ZADE

IPC: A61M5/172 ,  A61M5/142 ,  G16H40/67 ,  G16H20/17 ,  G16H50/70 ,  G16H10/60 ,  G16H50/30 ,  G16H40/40 ,  G16H20/60 ,  G01N33/49

Abstract: Disclosed are a device, system, methods and computer-readable medium products that provide an updated insulin-to-carbohydrate ratio and an updated total daily insulin. The described processes may be used for periodic updating of the insulin-to-carbohydrate ratio and the total daily insulin. The insulin-to-carbohydrate ratio and/or the total may be used in the calculation of new doses of insulin that a drug delivery device may be commanded to deliver to a user.

公开(公告)号：US20200324048A1

公开(公告)日：2020-10-15

申请号：US16898529

申请日：2020-06-11

Applicant: Insulet Corporation

Inventor： Jason O'CONNOR ,  Daniel ALLIS ,  David NAZZARO ,  John R. Bussiere ,  John D'ARCO

IPC: A61M5/172 ,  G16H40/63 ,  G16H20/17 ,  A61M5/142

Abstract: Systems and methods for automatically delivering medication to a user. A sensor coupled to a user can collect information regarding the user. A controller can use the collected information to determine an amount of medication to provide the user. The controller can instruct a drug delivery device to dispense the medication to the user. The drug delivery device can be a wearable insulin pump that is directly coupled to the user. The controller can be part of or implemented in a cellphone. A user can be required to provide a confirmation input to allow a determined amount of insulin to be provided to the user based on detected glucose levels of the user. The sensor, controller, and drug delivery device can communicate wirelessly.